The Trump administration has chosen not to finalize a rule proposed by the Biden administration that would have allowed ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Trump officials reject Medicare coverage ...

The proposal would have enabled more Americans to afford new medications in the GLP-1 class that have been shown to reduce weight.

Administration officials reversed a decision made during the Biden presidency that would have given millions of people access ...

Trump administration rejects a Biden plan to expand Medicare coverage of weight-loss drugs such as Zepbound and Wegovy.

Shares of Eli Lilly, the seller of Zepbound, were down 2.7% to $718.50 after the close on Friday. Novo Nordisk, the maker of Wegovy, saw its stock decline 1.4% to $61.67. Shares of Hims & Hers, a ...

The Biden administration proposal would have significantly expanded access to obesity to millions of Americans but would have cost the government billions.

The Trump administration has decided not to back a Biden administration plan that would have allowed Medicare to pay for ...

The stock market has been on edge since the announcement of tariffs, reporting its biggest loss since March 2020. The damage ...

Trump previously floated a 25% tariff on all imported drugs, though they were unaffected by recent reciprocal levies.

The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform.

President Trump wants to bring pharmaceutical manufacturing back to the United States. Experts warn that tariffs could result ...